Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Pre Treatment ◽

Tumor Expression

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.11.013 ◽

2021 ◽

Author(s):

Nefertiti C. duPont ◽

Danielle Enserro ◽

Mark F. Brady ◽

Katherine Moxley ◽

Joan L. Walker ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Advanced Stage ◽

Oncology Group ◽

Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.022 ◽

2012 ◽

Vol 124 (3) ◽

pp. 575-581 ◽

Cited By ~ 56

Author(s):

Chunqiao Tian ◽

Christine B. Ambrosone ◽

Kathleen M. Darcy ◽

Thomas C. Krivak ◽

Deborah K. Armstrong ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Common Variants ◽

Oncology Group ◽

Association between the N-terminally truncated (ΔN) p63α (ΔNp63α) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.07.035 ◽

2009 ◽

Vol 115 (3) ◽

pp. 424-429 ◽

Cited By ~ 3

Author(s):

Elizabeth L. Jewell ◽

Kathleen M. Darcy ◽

Alan Hutson ◽

Paula S. Lee ◽

Laura J. Havrilesky ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Progression Free Survival ◽

Advanced Stage ◽

Oncology Group ◽

Vegf Expression ◽

Free Survival ◽

Loss of p16 in advanced stage epithelial ovarian cancer is associated with chemoresistant disease, suboptimal debulking and poor progression-free survival: A Gynecologic Oncology Group study.

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.084 ◽

2012 ◽

Vol 125 ◽

pp. S37

Author(s):

A. Wallace ◽

K. Darcy ◽

A. Alvarez-Secord ◽

A. Hutson ◽

D. Tritchler ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Progression Free Survival ◽

Advanced Stage ◽

Oncology Group ◽

Free Survival ◽

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2006.02.014 ◽

2006 ◽

Vol 101 (3) ◽

pp. 390-397 ◽

Cited By ~ 26

Author(s):

Angeles Alvarez Secord ◽

Paula S. Lee ◽

Kathleen M. Darcy ◽

Laura J. Havrilesky ◽

Lisa A. Grace ◽

...

Keyword(s):

Ovarian Cancer ◽

Poor Prognosis ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Maspin Expression

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

BMC Cancer ◽

10.1186/s12885-019-5514-7 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

Young Shin Chung ◽

Sang-Yoon Park ◽

Jung-Yun Lee ◽

Jeong-Yeol Park ◽

Jeong-Won Lee ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Serous Carcinoma ◽

High Grade ◽

Advanced Stage ◽

Oncology Group ◽

An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2004.05.033 ◽

2004 ◽

Vol 94 (2) ◽

pp. 368-374 ◽

Cited By ~ 40

Author(s):

David H Moore ◽

James T Kauderer ◽

Jeffrey Bell ◽

John P Curtin ◽

Linda Van Le

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Oncology Group ◽

Alternative Treatments ◽

Oncology Group Study ◽

Factors Influencing

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.057 ◽

2012 ◽

Vol 125 ◽

pp. S24-S25 ◽

Cited By ~ 3

Author(s):

L. Landrum ◽

J. Java ◽

C. Mathews ◽

G. Lanneau ◽

L. Copeland ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Intraperitoneal Chemotherapy ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Nadir CA125 and second look surgery in patients with advanced stage epithelial ovarian cancer treated with intravenous compared to intraperitoneal chemotherapy: A study of Gynecologic Oncology Group Protocols 114 and 172

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.064 ◽

2012 ◽

Vol 125 ◽

pp. S28-S29

Author(s):

S. Richard ◽

A. Miller ◽

M. Markman ◽

D. Armstrong ◽

J. Walker ◽

...

Keyword(s):

Ovarian Cancer ◽

Intraperitoneal Chemotherapy ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Second Look

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

Journal of Gynecologic Oncology ◽

10.3802/jgo.2019.30.e112 ◽

2019 ◽

Vol 30 (6) ◽

Cited By ~ 2

Author(s):

Jung-Yun Lee ◽

Jae Weon Kim ◽

Myong Cheol Lim ◽

Sunghoon Kim ◽

Hee Seung Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽